SPL

0.00%

9.9¢ starpharma holdings limited

Ann: SPL7013 in VIRALEZE virucidal against Omicron, page-51

First 51 Last

Share
Profile

Follow
thrasher

4,925 Posts.

284

23/03/22

21:52

Post #: 60381821
Share

Originally posted by sarge17: ↑

A couple of things.
Firstly the questions of mine in the above post stemmed from the fact that I did not believe the 1st March press release adequately explained the figures and data provided by Starpharma. Having read the ASX release in full many times I still believe it could have explained things in a simpler and more clearer manner for what is quite a complex matter.

I also got peeved when my requests for clarification from the company went unanswered so I jumped the gun with my quite forthright and in hindsight incorrect statements in my post titled Viraleze is LESS effective against Omicron. That I’ll acknowledge. I subsequently received clarifying information direct from the company which fully explains the data for which I am satisfied and thankful.

After consideration I believe the info provided to me is not in-confidence or price-sensitive or such so I’m posting the response in full. Of note I have made numerous requests in the last 24 hrs to the Hotcopper moderators to close down my misleading thread and title but at the time of writing this post they have not seen fit to do so.

Cheers
Sarge

“Dear xxx
Antiviral/virucidal studies typically use log reductions to determine the percentage reductions of infectious viral particles, where a 1 log reduction (e.g., 103 to 102) is a 90% reduction, 2 log is a 99% reduction, 3 log is 99.9% reduction and so on. In this particular experiment, the Omicron strain's growth pattern was different to other strains of SARS-CoV-2 tested previously in that the viral titre (viral load) at baseline was lower than other strains at approximately 102.5. This lower starting point means that it isn’t possible to achieve greater than a 2.5 log reduction (or 99.6% reduction).

As noted in the announcement’s experimental details, SPL7013 achieved a maximum possible 2.5 log reduction (i.e., 102.5 to 100 = 1) , which is equivalent to a >99.6% reduction.

Given the baseline did not exceed 2.5, this was the maximum possible reduction that could be achieved in this experiment. If the viral load at baseline was higher e.g., 104 as we saw for Delta and other strains, and it reduced to 100, the percent reduction could have been as high as >99.99%. However, for Omicron this wasn’t possible as it didn’t achieve the baseline levels of other strains, so it wasn’t possible to achieve any more than a 2.5 log reduction (or 99.6% reduction).

It's not that SPL7013 is less effective against the Omicron strain but rather the Omicron strain's inability to replicate to the high levels seen with the other strains in previous antiviral experiments, which limited the maximum possible reduction to >99.6% in this experiment.
Thank you and kind regards.
Investor Relations”

Expand

Thank you for sharing sarge so HC not pulling down the thread even after your request they should, anyway the answer from Starpharma is excellent so you are not in the bad books after all and Viraleze is proven against Omicron and I would expect new strain also. Good result imo lets hope the TGA do the right thing. Thursday tomorrow lets all hope for some good news.

SPL Price at posting: 93.0¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

There are more pages in this discussion • 12 more messages in this thread...

First 51 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.9¢		Change 0.000(0.00%)		Mkt cap ! $41.31M

Open	High	Low	Value	Volume
10.0¢	10.0¢	9.9¢	$14.97K	151.0K

Buyers (Bids)

No.	Vol.	Price($)
3	372123	9.9¢

Sellers (Offers)

Price($)	Vol.	No.
10.0¢	5042	1

View Market Depth

No.	Vol.	Price($)
3	372123	0.099
2	140000	0.098
1	64565	0.097
1	50000	0.095
2	41737	0.094

Price($)	Vol.	No.
0.100	5042	1
0.105	99818	1
0.110	226808	10
0.115	122327	4
0.120	139405	10

Last trade - 16.10pm 27/09/2024 (20 minute delay)

SPL (ASX) Chart

Ann: SPL7013 in VIRALEZE virucidal against Omicron, page-51

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: SPL7013 in VIRALEZE virucidal against Omicron, page-51

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News